DUBLIN--(BUSINESS WIRE)--The "Global Cardiac Biomarkers Market 2017-2021" report has been added to Research and Markets' offering.
The global cardiac biomarkers market is forecast to grow at a CAGR of 12.97% during the period 2017-2021.
The report, Global Cardiac Biomarkers Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One driver in the market is increasing use of cardiac biomarkers. The use of cardiac biomarkers helps in assessing the risk associated with diabetes, which invariably affects the cardiovascular system of the individual. It also helps in providing the rapid and accurate diagnosis for critically ill patients with presumed ACS. This induces the high adoption of cardiac biomarkers among the end-users to treat people with various cardiac diseases. Based on the study conducted by Universidade Federal do Rio Grande do Sul and associated hospitals in 2017, the people with type 2 diabetes are observed to be having cardiovascular risks as well.
Key vendors
- Abbott
- Alere
- F. Hoffmann-La Roche
Key Topics Covered:
Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Research Methodology
Part 04: Introduction
Part 05: Market Landscape
Part 06: Market Segmentation By Technology
Part 07: Market Segmentation By Product
Part 08: Market Segmentation By End-User
Part 09: Geographical Segmentation
Part 10: Decision Framework
Part 11: Drivers And Challenges
Part 12: Market Trends
Part 13: Vendor Landscape
For more information about this report visit https://www.researchandmarkets.com/research/kmxfrb/global_cardiac